Greenwoods Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Greenwoods Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-220,000	Closed	-$3.21M	–	26
2017 Q4	$3.21M	Hold	220,000	–	–	0.27%	16
2017 Q3	$2.79M	Buy	220,000 +90,000	+69%	+$1.14M	0.23%	18
2017 Q2	$1.54M	Buy	+130,000	New	+$1.62M	0.18%	17

Other funds holding HZNP

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Greenwoods Asset Management's HZNP Position: Q1 2018 in Review

Greenwoods Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2018, closing a stake of 220,000 shares — an estimated $3.21M sold.

Greenwoods Asset Management first reported a position in HZNP in Q2 2017 and held it in 3 quarters. The position peaked at $3.21M in Q4 2017. 201 funds tracked by Wall St. Rank hold HZNP as of Q1 2018.

Greenwoods Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2018 after selling out during the quarter.
Greenwoods Asset Management sold 220,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2018, an estimated $3.21M.
Greenwoods Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017 and held it in 3 quarters.
Greenwoods Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.21M in Q4 2017.
201 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2018.

Based on Greenwoods Asset Management's 13F filing for Q1 2018, filed 14 May 2018.